World’s first weekly insulin Awiqli launched in India, now diabetes patients will have to take only 52 injections in a year

Denmark’s leading pharmaceutical company Novo Nordisk World’s first in India Basal insulin ‘Awiqli’ (Insulin Icodec) administered once a week Has been launched. With the advent of this new therapy, diabetic patients will not need to take insulin daily and the time taken throughout the year will be reduced. 365 injections reduced to only 52 Will remain.

this medicine Type 1 and Type 2 diabetes Is approved for adult patients suffering from and FlexTouch Pen Will be given through. India is the first in the world to launch this therapy sixth country Has become.

Big relief for diabetes patients

According to experts, the fear of taking daily insulin injections prevents many patients from starting treatment on time. Awiqli has come up with a solution to this problem.

Managing Director of Novo Nordisk India Vikrant Shrotriya Said that this is not just a new product but a practical solution for diabetes patients, which will make the treatment more easy and convenient.

What is the price of Awiqli?

The company has also kept its price competitive for the Indian market.

• 1 ml FlexTouch Pen (700 Units) – ₹2,611
• 3 ml FlexTouch Pen (2,100 units) – ₹7,833

If the average requirement of a patient is approximately 70 units per week If so, it will cost approximately ₹261–263 per week Will have to.

The company says that due to fewer injections, affordable price and strong distribution network, this product can reach a large number of patients.

How does this insulin work?

Awiqli is more concentrated than traditional insulin. In this 700 units per ml Contains insulin, which is slowly absorbed in the body and keeps blood sugar under control throughout the week.

According to experts, this reduces sudden fluctuations in blood sugar and Hypoglycaemia (extremely low blood sugar) The risk may also reduce.

Positive results found in clinical trials

Awiqli was compared with daily basal insulin during the ONWARDS clinical trial program.

The study found that this medicine—

• Was effective in reducing HbA1c levels.
• Was successful in keeping blood sugar under control for a longer period of time.
• Also performed on par or better than conventional insulin in terms of safety.
• Many patients were able to reach target HbA1c levels without hypoglycaemia.

Diabetes is a big challenge in India

India is among those countries in the world where the number of diabetes patients is highest.

on the assumption-

• 10.1 crore More than 100,000 people are suffering from diabetes.
• 13.6 crores People are in pre-diabetic state.
• About 9 lakhs People are affected by Type 1 Diabetes.

Despite this, relatively few patients are able to start insulin therapy even when needed, the main reason for which is considered to be the fear of daily injections.

There may be a big change in treatment

Health experts believe that the convenience of just one injection a week can increase patients’ compliance with treatment and help in starting insulin on time.

Novo Nordisk says this launch is a significant milestone in the field of diabetes treatment in India and can make treatment more convenient for millions of patients in the coming years.

Doctor’s advice necessary

Although Awiqli is an important innovation in diabetes treatment, experts strongly caution that patients should not make any changes to their current insulin therapy without consulting their doctor. Only a qualified endocrinologist or physician can decide for which patient this medicine is appropriate.